Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma

Sponsor
Hunan Province Tumor Hospital
Study ID
NCT02399566
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib, Pemetrexed — DRUG
    followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy.

Study Details

The purpose of this study is to compare effects of erlotinib and pemetrexed as maintenance therapy for lung adenocarcinoma. Primary Outcome is the progression free survival (PFS). Based on prediction of different potential benefit groups, this study may help the oncologist to optimize and improve the maintenance therapy plan for lung adenocarcinoma.

Key Dates

First listed
Mar 26, 2015
Start date
May 31, 2015
Status verified
Mar 2015
Primary completion
Jan 31, 2018
Completion
Jan 31, 2019

Study Design

Enrollment
300 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental
    followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy
  • Active Comparator: Comparator
    followed classical chemotherapy for 4 cycles, use Pemetrexed interventional for the maintenance therapy

Primary Outcome Measure

Progression free survival (PFS) [ Time Frame: two years ]

Central Contacts

Related Studies